Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06178991 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
A Phase 3 study, sponsored by BioNTech SE.
- Completed
- Registry status
- Phase 3
- Development phase
- 8,795
- Enrollment target
NCT06178991 is a Phase 3 study that has completed, run by BioNTech SE. The registered enrollment target is 8,795 participants.
The verdict
NCT06178991, a Phase 3 study, has completed, sponsored by BioNTech SE.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8,795 participants
- Enrollment target
Study Summary
The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to separate vaccines for the protection against influenza and SARS-CoV-2. Influenza and COVID-19 are diseases that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. Giving both influenza and COVID-19 vaccines together against influenza and SARS-CoV-2 could provide great benefits to both patients and caregivers in terms of simple and easy care. Around 8550 participants will be assigned into 1 of 8 vaccination groups (Group A, B, C, D, E, F, G or H) by chance. Cohort 1: Approximately 450 participants will be assigned by chance to one of the following: * Group A:Influenza and COVID-19 combination A vaccine, given at the same time in one arm and placebo (an injection consisting of just salt water and no medicines in it) in the opposite arm. * Group B: COVID-19 vaccine, given at the same time to one arm and licensed influenza vaccine in the opposite arm. Cohort 2: Approximately 4500 participants will be assigned by chance to one of the following: * Group C: Influenza and COVID-19 combination B vaccine, given at the same time in one arm and placebo in the opposite arm. * Group D: COVID-19 vaccine, given at the same time in one arm and licenced influenza vaccine in the opposite arm. Cohort 3: Approximately 3600 participants will be assigned by chance to one of the following: * Group E: Influenza and COVID-19 combination B vaccine. * Group F: COVID-19 vaccine. * Group G: Licenced influenza vaccine. * Group H: Investigational influenza vaccine. All participants in cohort 1 and cohort 2 will receive 2 injections and participants in cohort 3 will receive 1 injection as per their assigned study group at Visit 1. The participants will be followed for about 6 months. During this time, researchers will assess safety and the body's reaction to the vaccination over approximately 6 m
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL COVID-19 Vaccine
- BIOLOGICAL Licensed influenza vaccine
- BIOLOGICAL Influenza and COVID-19 Combination A
- BIOLOGICAL Influenza and COVID-19 Combination B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,795 participants |
| Start Date | 2023-12-20 |
| Est. Completion | 2024-11-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06178991
The ClinicalTrials.gov registry entry for NCT06178991 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 8,795 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioNTech SE, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT06178991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06178991 about?
NCT06178991 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.". The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to separate vaccines for the protection against influenza and SARS-CoV-2. Influenza and COVID-19 are diseases that can spread easily from one person to an...
What is the current status of trial NCT06178991?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8,795 participants. The study started on 2023-12-20. Estimated completion is 2024-11-26.
What interventions are being tested in trial NCT06178991?
The interventions under investigation include: Placebo (BIOLOGICAL), COVID-19 Vaccine (BIOLOGICAL), Licensed influenza vaccine (BIOLOGICAL), Influenza and COVID-19 Combination A (BIOLOGICAL), Influenza and COVID-19 Combination B (BIOLOGICAL).
Who is sponsoring clinical trial NCT06178991?
This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.